SR9009
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H24ClN3O4S |
| Molar mass | 437.94026 |
| 3D model (JSmol) | |
| |
| |
SR9009 also known as Stenabolic is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)[1] with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ.[2]
Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.[3]
See also
References
- ↑ Dodson B (2013-08-20). "New drug mimics the beneficial effects of exercise". Health and Wellbeing. Gizmag. Retrieved 2013-08-21.
- ↑ Solt LA; Wang Y; Banerjee S; Hughes T; Kojetin DJ; Lundasen T; Shin Y; Liu J; Cameron MD; Noel R; Yoo SH; Takahashi JS; Butler AA; Kamenecka TM; Burris TP (May 2012). "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature. 485 (7396): 62–8. PMC 3343186
. PMID 22460951. doi:10.1038/nature11030. Lay summary – Nature Magazine. - ↑ Woldt E; Sebti Y; Solt LA; Duhem C; Lancel S; Eeckhoute J; Hesselink MK; Paquet C; Delhaye S; Shin Y; Kamenecka TM; Schaart G; Lefebvre P; Nevière R; Burris TP; Schrauwen P; Staels B; Duez H (August 2013). "Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy". Nat. Med. 19 (8): 1039–46. PMC 3737409 . PMID 23852339. doi:10.1038/nm.3213. Lay summary – Voice of America (2013-07-19).
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.